Trial Details

Recruiting
Basic Information
Clinical ID c5432
Identifier ACTRN12622001458729
Trial Title Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Inflammatory bowel disease;Crohn's disease;Ulcerative colitis; Inflammatory bowel disease Crohn's disease Ulcerative colitis;Oral and Gastrointestinal - Inflammatory bowel disease;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointe
Interventions The interventional arm will receive subcutaneous (SC) infliximab and the dosing will be stratified according to prior intravenous (IV) infliximab dosing regimen.120 mg SC infliximab 2-weekly - patients previously receiving IV infliximab at doses o
Participant Information
Sponsor The Alfred Hospital
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase PHASE3|PHASE4
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL